Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2022 / Jan / What’s New in Biopharma?
Pharma and Biopharma

What’s New in Biopharma?

New frontiers in call and gene therapy characterization, quick tips for analytical ultracentrifugation, and a revolution in flow cytometry… We present the latest research and business biopharma news.

By James Strachan 01/31/2022 1 min read

Share

Mass photometry in AAV characterization. A big challenge facing the gene therapy field is developing analytical tools to ensure purity and safety of the vectors used to deliver genes – such as recombinant adeno-associated viruses (AAVs). Now, researchers from the National Heart, Lung, and Blood Institute, USA, have applied the recently developed single-molecule technique, mass photometry (MP) – which measures mass distributions of biomolecules – to AAV characterization. They found that MP can measure heterogeneity, relative species content, packing efficiency, and other attributes of AAVs accurately, reproducibly, quickly, and with minimal sample preparation. “Those attributes make MP an attractive tool for the biophysical characterization of viral vectors in industry and academic applications,” the researchers concluded (1). 

Separating the genes from the chaff. Another challenge in AAV production is the presence of capsids that lack the required gene of interest, causing purity issues and potentially immune responses that reduce the effectiveness of the therapy. In a recent study, a team of Pall researchers used a novel anion exchange chromatography elution method to separate empty and full AAVs. Initially the results did not meet the team’s separation expectations, which they thought was related to membrane chromatography devices tending not to have a sufficiently large number of theoretical plates. So they switched to a step gradient, which provided better AAV enrichment (2). 

Agilent teams up with Lonza. Sticking with analytical challenges in advanced medicine, Lonza and Agilent are collaborating to integrate new analytical technologies into Lonza’s Cocoon – an automated and closed platform for cell therapy manufacturing. The idea is to bring real-time information on Critical Quality Attributes (CQA) so that the manufacturing process can be “directed” in real time. This approach could be particularly valuable for autologous cell therapies, such as approved CAR T-cell therapies Yescara and Kymriah, because of the inherent variability of the starting material – cells taken from a patient, which are then genetically modified and infused (3). 

Best practices for aggregate analysis. The cell and gene therapies mentioned above look to large-molecule therapies – especially protein therapeutics – as a model for rapid progression from an emerging to an established therapy. As such, many analytical techniques that help ensure the quality of protein therapeutics are now well established; for example, analytical ultracentrifugation (AUC) is used to characterize soluble aggregates that can reduce drug efficacy and safety. In a recent review article, industry and academic researchers explore the key considerations and best practices for aggregate analysis – summarized in a handy table (4).

In other news… 
 

Protein Metrics will sell their Byos software with Agilent’s liquid chromatography-mass spectrometry (LC-MS) systems and will work on common applications as part of collaboration (5) 

PreOmics – developer of automation and sample prep tools for MS-based proteomics, spun out of Matthias Mann’s lab – raises €13.5m in Series B financing provided by Bruker (6) 

Depixus, a biotech developing technology that immobilizes DNA within a flow cell to detect changes, such as base modification patterning, raises €30.6 million in Series A financing (7). 

Scientists at Scripps Research use high-resolution, low-temperature electron microscopy (cryo-EM) to rapidly characterize antibodies – elicited by a vaccine or infection – that bind to a desired target on a virus at the atomic level (8) 

Researchers use high-speed fluorescence image-enabled sorting to isolate cells with complex cellular phenotypes (9)

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Di Wu et al., Gene Therapy (2022). https://doi.org/10.1038/s41434-021-00311-4 
  2. AL Hejmowski et al., Biotechnology Journal (2021). https://doi.org/10.1002/biot.202100219   
  3. Agilent et al. (2021). Available at: https://bit.ly/32nbasY
  4. GM Bou-Assaf et al. (2022). Available at: https://doi.org/10.1016/j.xphs.2021.12.023 
  5. Cision (2022). Available at: https://bit.ly/3IvwsnL 
  6. Select Science (2022). Available at: https://bit.ly/3KH1n2i 
  7. Cision (2021). Available at: https://prn.to/3qOq5Wq 
  8. A Antanasijevic et al. (2022). https://doi.org/10.1126/sciadv.abk2039 
  9. D Schraivogel et al., Science, 375, 6578, 315-320 (2022). https://doi.org/10.1126/science.abj3013

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.